Celecoxib showed the inhibition of proliferation and survival by downregulating β-catenin in Ph+ CML (120), restoring imatinib sensitivity in imatinib-resistant CML (121), and exerting an anti-tumor effect in the HL-60 AML cell line (122), yet its relationship with cadherin-11 is not yet specified. This evidence concerns the gene CDH11 and chronic myelogenous leukemia, BCR-ABL1 positive.